In the present study, we demonstrate that phosphorylation of ALK is higher in PARP inhibitor-resistant ovarian and breast cancers compared with their PARP inhibitor-sensitive counterparts and present evidence implicating the ALK–CDK9 axis as a driver of PARP inhibitor resistance which can be effectively overcome by selective ALK inhibitors. The gene discussed is ALK; the disease is breast carcinoma.